New Patent Extends the Reach of NIMBUS Technology to Combining Bonded and Releasable Agents
GAINESVILLE, Fla., Aug. 31, 2011 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it had been awarded a fifth U.S. patent for its novel, non-leaching NIMBUS® antimicrobial technology.
The United States Patent and Trademark Office has issued Quick-Med Technologies U.S. Patent No. 8,007,921 entitled "Gypsum Board Containing Antimicrobial and Antibacterial Compounds." Quick-Med's invention not only addresses a process for rendering gypsum wall board antimicrobial but also covers the non-leachable bonding of an antimicrobial from the NIMBUS family of polycations which performs two functions. First, it acts as an antimicrobial agent. Second, it serves as a stabilizer for a non-polymeric second antibacterial in the form of an ionic compound that is slowly released in the presence of moisture. The combination represents a most effective treatment that acts to prevent the growth of a broad spectrum of bacteria and fungi. The value of this combination is in its ability to prevent the proliferation of odor and stain causing microorganisms.
Dr. Jerry Olderman, Quick-Med's vice president of Research & Development and co-inventor said, "With this fifth patent from our original invention, we have not only covered an attractive new NIMBUS application but also extended our underlying NIMBUS technology. We are excited to have received this patent."
"This new patent comprises a strong selection of claims for the choice of materials and the simple, low cost process of treating wallboard components. It also represents a broad opportunity to combine an antimicrobial with a second releasable agent to perform a second task," says Dr. William Toreki, co-inventor and Chief Chemist with Quick-Med Technologies, Inc.
The new patent was issued on August 30, 2011 with an expiration date of February 25, 2024. Quick-Med has five additional NIMBUS patents pending at the USPTO.
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. Quick-Med commercialized its NIMBUS technology in traditional wound care products in 2009 and is developing NIMBUS applications in several other medical device areas including adhesives, foams, hydrogels, films, hydrocolloids, and catheters. Additionally, its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.